// App-Quantinova.ai

: Thalidomide Combined with Interferons for the Treatment of Recurrent or Refractory Non-Hodgkin's Lymphoma

Researchers

Presenter

  • Fangfang Yuan

Principal Investigators

  • Hao Ai

  • Qingsong Yin

  • Lin Chen

  • Ruihua Mi

  • Xudong Wei

  • Yongping Song

  • Delong Liu

Medical Centers

  • Tumor Hospital of Zhengzhou University/Henan Cancer Hospital, zhengzhou, China

  • Tumor Hospital of Zhengzhou University, Department of Hematology, Zhengzhou, China

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • Tumor Hospital of Zhengzhou University/Henan Cancer Hospital, zhengzhou, China

  • Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

  • Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China

  • New York Medical College, Hawthorne, NY

Locations

  • China

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

  • Autoimmune (AI)

  • Gastroenterology (GU)

  • Oncology (ONC)

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Non-Hodgkin's Lymphoma

  • Deep vein thrombosis

  • Mantle cell lymphoma

  • Hodgkin's Lymphoma

  • Anaphylaxis

  • B cell lymphomas

  • Constipation

  • Non‐Hodgkin Lymphoma

  • Arrhythmia

  • Venous thrombosis

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Thalidomide

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved